1. Home
  2. KNTE

KNTE

Kinnate Biopharma Inc.

Logo Kinnate Biopharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

0

Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 125.5M IPO Year: 2020
Target Price: $7.32 AVG Volume (30 days): 402.9K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.42 EPS Growth: N/A
52 Week Low/High: $1.04 - $7.18 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: